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Abstract
Parkinson’s disease (PD) is a common, late-onset movement disorder with selective degeneration of dopaminergic (DA)
neurons in the substantia nigra (SN). Although the neurotoxin 6-hydroxydopamine (6-OHDA) has been used to induce
progressive degeneration of DA neurons in various animal models of PD, the precise molecular pathway and the impact of
anti-apoptotic treatment on this neurodegeneration are less understood. Following a striatal injection of 6-OHDA, we
observed atrophy and progressive death of DA neurons in wild-type mice. These degenerating DA neurons never exhibited
signs of apoptosis (i.e., caspase-3 activation and cytoplasmic release of cytochrome C), but rather show nuclear translocation
of apoptosis-inducing factor (AIF), a hallmark of regulated necrosis. However, mice with genetic deletion of the
proapoptotic gene Bax (Bax-KO) exhibited a complete absence of 6-OHDA-induced DA neuron death and nuclear
translocation of AIF, indicating that 6-OHDA-induced DA neuronal death is mediated by Bax-dependent AIF activation. On
the other hand, DA neurons that survived in Bax-KO mice exhibited marked neuronal atrophy, without significant
improvement of PD-related behavioral deficits. These findings suggest that anti-apoptotic therapy may not be sufficient for
PD treatment, and the prevention of Bax-independent neuronal atrophy may be an important therapeutic target.
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Introduction
Parkinson’s disease (PD) is one of the most common
neurodegenerative disorders characterized by a progressive loss
of dopaminergic (DA) neurons in the substantia nigra (SN), which
leads to the typical symptoms, including tremor, rigidity, and
bradykinesia [1,2,3,4]. Although recent advances have been made
in defining biochemical events underlying PD, a precise
mechanism of DA neuronal death in PD pathology is yet to be
elucidated. In a neurotoxin-induced animal model of PD, large
bodies of studies support the apoptotic nature of DA neuronal
death. Neuronal apoptosis is mediated by the activation of the pro-
apoptotic Bcl-2 family protein Bax, and mitochondrial transloca-
tion of Bax triggers the release of cytochrome C into the cytosol,
which promotes apoptosome formation and subsequent caspase-3
activation [5,6]. Intraperitoneal injection of the neurotoxin 1-
methyl-1,2,3,6-tetrahydropyridine (MPTP) immediately induced
cytoplasmic release of cytochrome C, cleavage of caspase-3, and
subsequent increase in terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) [7,8,9,10]. Supporting this,
genetic deletion of the pro-apoptotic gene Bax (Bax-KO), or
overexpression of the anti-apoptotic gene Bcl-2, suppressed
MPTP-induced DA neuronal death [11,12]. Although these lines
of evidence implicate apoptosis, other lines of evidence also suggest
the involvement of other types of cell death, such as autophagy
and necrosis [13,14,15,16].
Whereas MPTP treatment or administration of neurotoxin 6-
hydroxydopamine (6-OHDA) into the SN or medial forebrain
bundle quickly induce DA neuronal death within 1 week [12,17],
striatal injection of the 6-OHDA evokes delayed and progressive
DA neuronal degeneration (.6weeks), which resembles the
human PD pathology [2,18,19]. It is far less certain which
mechanism of progressive DA neuronal death is induced by
striatal injection of 6-OHDA. Although apoptotic profiles based
on morphological assessment and TUNEL labeling have been
observed in the rat SN following 6-OHDA lesion [20,21,22,23],
results from other groups did not support this finding [24,25]. This
is partly attributable to the ambiguity of markers for the
identification of the specific types of cell death. For instance,
although TUNEL has been widely used as a hallmark for
apoptosis, it in fact also detects necrotically degenerating cells
[26]. Furthermore, Bcl-2 family molecules not only affect caspase-
dependent apoptosis, but also other types of cell death [27].
Accordingly, knockout of the pro-apoptotic gene Bax or
overexpression of Bcl-2 proteins can prevent some types of
necrosis [28].
In this study, we identified that progressive DA neuronal death
induced by striatal injection of 6-OHDA is not dependent on
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and apoptosis-inducing factor (AIF). However, 6-OHDA-induced
DA neuronal atrophy and early phases of neurodegeneration were
also observed in Bax-KO mice. In addition, there was no
significant improvement of PD-related behavioral deficits, sug-
gesting that anti-apoptotic therapy may not be sufficient, and that
prevention of Bax-independent neuronal atrophy is an important
therapeutic target.
Results
Effect of striatal injection of 6-OHDA on DA neuronal
degeneration in wild-type (WT) and Bax-KO mice
To test the contribution of Bax-dependent DA neuronal death
in 6-OHDA-induced PD mouse model, we first explored the
extent of DA neuronal death in WT and Bax-KO mice (Fig. 1).
Following striatal injection of 6-OHDA in WT mice, there was a
progressive decrease in the number of TH+ DA neurons in the
midbrain. Sterological quantification of DA neurons in the
substantial nigra (SN) and ventral tagmental area (VTA)
demonstrated that the numbers of DA neurons in Bax-KO mice
were significantly greater than those in WT mice, suggesting that
developmental programmed cell death of DA neurons are
dependent on the function of Bax gene. The reduction of TH+
neurons was evident in 2 weeks after 6-OHDA injection, and at 6
weeks, approximately 50% (VTA) and 70% (SN) of TH+ neurons
disappeared in WT mice (Fig. 1K, L). However, Bax-KO mice did
not exhibit significant DA neuronal death in 2 weeks after 6-
OHDA treatment, and 90% (VTA) and .60% (SN) of TH+
neurons survived 6 weeks after treatment (Fig. 1K, L), suggesting
that DA neuronal death after 6-OHDA treatment is mediated by a
Bax-dependent pathway.
Although we found that most Bax-KO DA neurons survived for
up to 2 weeks after 6-OHDA treatment, these surviving neurons
appeared to have reduced TH expression, similar to WT mice
(Fig. 1E vs. 1F and 1H vs. 1I, insets). Quantification of TH-
immunoreactivity confirmed this visual impression. DA neurons in
WT and Bax-KO contralateral sides exhibited a similar
distribution of TH-intensity (Fig. 1M), and a similar reduction in
TH-intensity was found in both WT and Bax-KO ipsilateral sides
at 2 weeks after 6-OHDA injection (Fig. 1N–P). Our finding
implies that some aspects of neurodegeneration (such as neuronal
atrophy and loss of TH expression) are dissociated from the Bax-
dependent cell death pathway, and thus occurred normally in Bax-
KO mice. Supporting this idea, there was a significant reduction in
soma size within 2 weeks after 6-OHDA injection both in WT and
Bax-KO mice (Fig. S1). On the other hand, a significant fraction
of TH+ neurons in 6 weeks-old Bax-KO mice exhibited a partial
recovery of TH-intensity and soma size (Fig. 1J, inset, Fig. 1N,P
and Fig. S1), suggesting that a subset of Bax-KO-rescued DA
neurons restored TH expression.
Absence of 6-OHDA-induced DA neuronal death in Bax-
KO mice
Considering that Bax-KO DA neurons progressively lost TH
expression after 6-OHDA treatment, it was unclear whether a
subset of DA neurons ultimately underwent cell death in a Bax-
independent manner, or whether they survived but completely lost
TH expression. To address this issue, we tested the phosphory-
lation of c-Jun (P-Jun) in ipsilateral DA neurons. Previously, we
demonstrated that P-Jun was maintained in the surviving, but
atrophied, neurons rescued from programmed cell death during
development and after nerve injury in Bax-KO mice [29,30].
Following 6-OHDA injection, many TH+ neurons exhibited
enhanced phosphorylation of c-Jun in WT mice by 2 weeks
(Fig. 2B), but P-Jun+ cells were barely detected in the 6-weeks-old
SN (Fig. 2C), which may be due to the death of WT DA neurons.
On the other hand, many P-Jun+ cells were found in the Bax-KO
SN 2 and 6 weeks after 6-OHDA treatment (Fig. 2D–F). A subset
of these P-Jun+ cells did not exhibit TH immunoreactivity (Fig. 2F,
green arrowheads), suggesting that these are surviving DA neurons
that completely lost TH expression. When P-Jun+/TH2 cells
were included in the number of surviving DA neurons, it
appeared that most DA neurons survived for up to 6 weeks after
6-OHDA injection in Bax-KO mice (Fig. 2G: P-Jun+/TH2,
F(3, 10)=11.945, P,0.01). To confirm this, we injected an Alexa
488-conjugated retrograde tracer (Cholera toxin subunit B, CTx-
B) into the striatum 7 days prior to 6-OHDA injection, and the SN
was monitored 6 weeks after 6-OHDA treatment (Fig. 2H–K). On
the contralateral side, most (.97%) CTx-B-labeled cells were
TH+ DA neurons in both WT (data not shown) and Bax-KO mice
(Fig. 2I). However, a substantial number of retrograde-labeled cells
failed to exhibit TH expression in Bax-KO mice (Fig. 2J),
suggesting that these DA neurons had innervated the striatum
before 6-OHDA injection. Furthermore, most of CTx-B-labeled
cells in Bax-KO mice exhibited strong P-Jun immunoreactivity
(Fig. 2Jb). These results suggest that DA neurons progressively
undergo atrophic (reduced soma size, reduced TH expression and
increased P-Jun) alterations before the actual death caused by 6-
OHDA injection (2 weeks), which is similar to that seen in Bax-
KO mice. These atrophied neurons in WT mice ultimately
undergo cell death during a 2- to 6-weeks period, but Bax-KO
appears to completely rescue these DA neurons from cell death.
However, a subset of DA neurons (,50%) recovered their TH
expression, whereas a subset of neurons underwent extensive
atrophy, with marked shrinkage of soma size and complete loss of
TH expression (Fig. 2K).
DA neuronal death induced by 6-OHDA is a caspase-
independent, but AIF-mediated, process
Whereas Bax-dependent cell death is generally considered as
caspase-dependent apoptosis, we were not able to detect any
activated caspase-3-labeled cells in a minimum of 20 sections
containing the SN from WT and Bax-KO (n=3–4/group) mice
(Fig. 3A–D). Because we occasionally identified activated caspase-
3-labeled, spontaneously dying adult-produced neurons in the WT
dentate gyrus (DG, inset of Fig. 3C), the absence of activated
caspase-3 labeling in the ipsilateral SN is not attributable to an
artifact of staining. By mitochondrial fractionation and subsequent
western blot analysis, we also failed to monitor cytosolic release of
cytochrome C, while Bax was partially translocated to the
mitochondria in WT (Fig. 3E). Therefore, we asked whether
other forms of neuronal death, such as necrosis and autophagy, are
involved in 6-OHDA-induced, Bax-dependent DA neuronal
death. Although autophagy has been implicated in the DA
neuronal death in some models [31], we failed to detect signs for
autophagy, such as LC3 conversion and Beclin1 induction (data
not shown), we found that about 20% of TH+ cells exhibited
translocation of AIF from the mitochondria to the nucleus in the
ipsilateral WT SN, whereas AIF-immunoreactivity was predom-
inant in the cytoplasm/mitochondria of the control side (Fig. 3F–
X, Y). All AIF-translocated DA neurons exhibited reduced levels
of TH expression, indicating that they were degenerating neurons.
Interestingly, these WT DA neurons with nuclear AIF signals
maintained cytochrome C immunoreactivity in the mitochondria
(Fig. 3K, L). Because release of cytochrome C from mitochondria
is an essential step for apoptosis, it appears that 6-OHDA
treatment selectively triggered the release of AIF. In Bax-KO
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25346Figure 1. 6-OHDA-induced DA neuronal death in wild-type (WT, A–C) and Bax-KO (D–F) mice. A–D:W T( A,B) or Bax-KO (C,D) mice were
sacrificed 6 weeks after striatal injection of 6-OHDA, and dopaminergic (DA) neurons in the control (A,C) and ipsilateral (B,D) midbrain were
visualized by immunolabeling of tyrosine hydroxylase (TH). Dashed line indicates in A substantia nigra (SN) and dotted line indicates ventral
tagmental area (VTA). E–J: DA neurons in the SN 2 weeks (F,I) or 6 weeks (G,J) after striatal injection of 6-OHDA. Scale bar=50 mm. Controls (CON,
E,H) show TH immunolabeling in the contralateral side of the SN 6 weeks after 6-OHDA injection. Insets show large magnification images of TH-
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that Bax is necessary for AIF activation.
Partial recovery of striatal DA innervation in Bax-KO mice
Because at least a subset of DA neuronal cell bodies recovered
TH immunoreactivity at 6 weeks of 6-OHDA treatment in Bax-
KO mice, we next tested whether these DA neurons exhibited
striatal innervation (Fig. 4). In the ipsilateral side of WT brains, the
intensity of TH-labeling was progressively reduced in all
anatomical levels we examined, including the nigrostriatal bundle
(NSB), posterior striatum (proximal to the DA cell bodies), and
anterior striatum (distal to the DA cell bodies; Fig. 4B,F, and J).
The TH levels were similarly reduced at 2 weeks after 6-OHDA
treatments, whereas Bax-KO mice exhibited substantially more
TH+ fibers in the ipsilateral side of the NSB (Fig. 4D) and
posterior striatum (Fig. 4H) on 6 weeks. Although there was a
marked reduction of TH+ fibers in the ipsilateral anterior striatum
compared to the contralateral side, large magnification images
demonstrated that significantly more amounts of TH+ fibers were
maintained in the ipsilateral side of Bax-KO mice, compared to
the that of WT mice (Fig. 4L). Quantification of TH-immunore-
activity in posterior (Fig. 4M) and anterior (Fig. 4N) striatum
demonstrated the spared TH+ fiber innervations in the posterior
striatum in Bax-KO mice on 6 weeks, suggesting that surviving
DA neurons in Bax-KO mice restored their striatal innervation,
especially in the posterior striatum.
Figure 2. Complete prevention of DA neuronal death in Bax-KO mice. A–D: Immunofluorescence labeling of TH (red) and phosphorylated c-
Jun (P-Jun, green) in 2-weeks CON (A,D), 2-weeks IPSI (B, E), and 6-weeks IPSI (C,F) sides of WT (A–C) and Bax-KO (D–F) mice. Nuclei were
counterstained with Hoechst33342 (blue). Scale bar=20 mm. Green arrowheads indicate P-Jun+/TH2 cells, and pink arrows indicate P-Jun+/TH+ cells.
G: Quantification of the proportion of P-Jun- and/or TH-labeled cells in the SN of WT and Bax-KO mice. Data are expressed as mean6s.e.m. n=3, H:
Experimental scheme. Alexa 488-conjugated tracer choleratoxin B subunit(Ctx-B) was injected 1-week prior to striatal 6-OHDA injection. Animals were
sacrificed 6 weeks after 6-OHDA injection, and retrograde-labeled cells in the SN were examined. I,J: Retrograde tracing with CTx-B(green) and
immunofluorescence labeling of TH (red) in CON (I) and IPSI (J) sides of Bax-KO mice. Arrows in J indicate theCTx-B-labeled, but TH-negative (CTB+/
TH2) cells. Arrowheads indicate the CTx-B-labeled, and TH-expressing cells. Inset in I shows normal CTx-B-labeled TH+ cells with dendritic processes.
Insets show the higher magnification image of CTx-B+/TH2 cells (Ja) and CTx-B+/P-Jun+ cells (Jb). Note these cells have reduced soma size and
reduced/absence of dendritic processes, which are hallmarks of atrophic modification. Nuclei were counterstained with Hoechst33342 (blue). Scale
bar=20 mm. K: Summary for the fate of DA neurons in WT and Bax-KO SN after 6-OHDA treatments. Both WT and Bax-KO DA neurons atrophied, with
reduced TH expression and induction of P-Jun at early phases of neurodegeneration (2 weeks). Whereas most DA neurons in WT mice underwent cell
death within 6 weeks after 6-OHDA injection, virtually all Bax-KO DA neurons survived and exhibited segregation into normally recovered DA neurons
(with TH expression and no/reduced P-Jun) and severely atrophied DA neurons (with no TH expression and the maintenance of P-Jun).
doi:10.1371/journal.pone.0025346.g002
labeled cells. K,L: Quantification of TH+ cells in the SN (K) and VTA (L) of WT and Bax-KO mice. Data are expressed as mean6s.e.m. n=4–5, *P,0.05
in Student’s t test comparison with control (CON) vs. ipsilateral (IPSI) sides, and **P,0.05 in Student’s t-test comparison with WT vs. Bax-KO mice.
M,N: Comparison of the intensity of THimmunoreactivity between 2-weeks WT (open bars) vs. 2- (grey bars) or 6-weeks (black bars) Bax-KO groups in
CON (M) and IPSI (N) sides. O,P: Comparison of THimmunoreactivity between CON and IPSI sides in 2-weeks WT (O) vs. 2- and 6- weeks Bax-KO (P)
groups.
doi:10.1371/journal.pone.0025346.g001
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6-OHDA. Total DA levels (ng/mg protein) in the control sides
were similar in WT and Bax-KO mice (WT, 612688; Bax-KO,
520692, t(5)=0.7003, P=0.515 in Student’s t-test). While DA
levels in the ipsilateral side of WT was under the detection limit in
our measurements, small but significant level of DA was
monitored in the ipsilateral side of Bax-KO mice (35610, n=4),
suggesting that DA innervation is partially spared in Bax-KO
mice.
Bax-KO does not prevent striatal degeneration and
functional deficits
Although substantially more amounts of striatal innervation of
DA neurons were found in Bax-KO mice, Bax-KO mice did not
exhibit functional improvements in two different behavioral tests
assessing PD-related neurological impairments (Fig. 5). Because 6-
OHDA-induced nigrostriatal degeneration promotes asymmetric
use of limbs, the cylinder test has been used to assess unilateral
forelimb akinesia [32,33]. In this test, both WT and Bax-KO mice
showed a similar time course of forelimb use asymmetry (Fig. 5A).
The apomorphine rotation test [32] also showed a similar extent of
functional impairment of the nigrostriatal system in WT and Bax-
KO mice (Fig. 5B). Collectively, these results suggest that
increased survival of DA neurons by Bax deletion had no
functional benefits.
Discussion
In this study, we provide evidence that Bax is indispensable for
the 6-OHDA-induced DA neuronal death, and virtually all Bax-
KO DA neurons survived until 6 weeks after 6-OHDA treatment.
Although all DA neurons were rescued from cell death in Bax-KO
mice, a large subset (.40%) of surviving neurons at 6 weeks
maintained their atrophied morphology, such as reduction in soma
size, loss of TH expression, and increased P-Jun. Previously, we
have characterized that the absence of trophic signals or neuronal
damage triggered P-Jun, which is an upstream event for Bax
activation [29]. Furthermore, P-Jun was also increased in dying rat
DA neurons following striatal 6-OHDA injection [34]. Therefore,
we employed P-Jun as a marker for atrophied neurons.
Interestingly, neuronal atrophy was similar in both WT and
Bax-KO DA neurons at early phases (2 weeks after 6-OHDA
injection) of neurodegeneration, suggesting that DA neuronal
atrophy occurs independently of the Bax-dependent cell death
pathway, and the blockade of neuronal death by Bax deletion is
not sufficient for preventing neuronal atrophy. In fact, dissociation
of neuronal death and atrophy is commonly observed in Bax-KO
mice during development [35,36], after nerve axotomy [30,37],
and in an amyotrophic lateral sclerosis model [38], indicating that
the neuronal death and neuronal atrophy are mediated by two
independent mechanisms.
By 6 weeks after 6-OHDA injection, most WT DA neurons had
degenerated, and accordingly, few P-Jun-labeled neurons re-
mained. However, DA neurons in Bax-KO mice appeared to be
segregated into two distinct populations. A subset (,50%) of DA
neurons completely lost TH expression and exhibited a strong P-
Jun expression. Others exhibited substantial recovery of TH
expression, but lost P-Jun. Similar segregation of surviving neurons
was previously found in developing motoneurons (MNs) of Bax-
KO mice [36,39]. During development, usually 50% of initially
Figure 3. AIF-mediated DA neuronal death following striatal 6-OHDA injection. A–D: Immunofluorescence labeling of activated caspase-3
(green) and TH (red) in CON (A, B) and IPSI (C, D)S No fW T( A, C) and Bax-KO (B,D) mice 2 weeks after 6-OHDA injection. Inset in C shows activated
caspase-3 immunoreactive cells in the dentate gyrus (DG) of WT mice. Nuclei were counterstained with Hoechst33342 (blue). Scale bar=20 mm. E:
Western blot analysis of subcellular distribution of Bax and cytochrome C 2 weeks after 6-OHDA injection. Cytosolic and mitochondrial fractions were
isolated from micropunched SN area from control and ipsilatral sides.F–O: Triple immunofluorescence labeling of cytochrome C (F, K, P, T, red), AIF
(G, L, Q, U, green), and TH (H, M, R, V, blue) in CON (F–I, P–S) and IPSI (K–N, T–X) sides of WT (F–N) and Bax-KO (P–S) SN. J and O show the z-
stacked images demonstrating cytosolic (J) vs. nuclear localization (O) of AIF. Nuclei were counter-stained with Hoechest33342 and pseudo-colored
in purple. Merged images of cytochrome C and AIF in WT (I,N) and Bax-KO (S,X) SN are shown. Insets demonstrate the higher magnification images.
Y: Quantification of the DA neurons exhibiting nuclear-translocated AIF signals in the SN. Data are expressed as mean6s.e.m. n=4, *P,0.01 in
Student’s t-test comparison.
doi:10.1371/journal.pone.0025346.g003
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and thus Bax-KO mice maintain a two-fold increase in the
number of surviving MNs than that of their WT littermates [36].
However, these surplus MNs did not maintain innervation to the
target muscle, and exhibited severe atrophic modifications,
including reduced cell size and P-Jun expression, and loss of
choline acetyltransferase (ChaT) expression. By elimination of
surplus MNs from the target connection, normal numbers of MNs
innervated the target muscle, and Bax-KO mice did not exhibit
motor-related deficits [29,36]. We do not believe that this
segregation is owing to the molecular differences because increase
in the neurotrophic signals restored innervating ability of
atrophied MNs [37]. Similarly, we found that only a subset of
DA neurons restored the striatal innervation, and differential
ability of target (striatal) innervation of surviving DA neurons may
be involved in the segregation process, although the precise
mechanism is required to be elucidated in the future.
Although most forms of Bax-dependent cell death involve
caspase-dependent apoptosis, here we found that striatal injection
of 6-OHDA promoted Bax-dependent, but caspase-independent
DA neuronal death. Neither caspase-3 activation nor cytochrome
C release was found in degenerating DA neurons (i.e., atrophied
neurons with marginal TH expression) after 6-OHDA injection.
Because we infrequently observed activated caspase-3 labeling in
spontaneously degenerating, adult-generated neurons in the DG in
the same section, we believe that the absence of activated caspase-
3 labeling in DA neurons was not due to poor staining or simply
missing the labeled cells. Although previous reports demonstrated
caspase-3 activation in a mouse model of PD with MPTP
treatment [40,41,42], human PD brain samples [43,44], and in
vitro models with 6-OHDA [16,45,46,47], there is no report
demonstrating caspase-3 activation in a mouse or rat model of
striatal 6-OHDA injection in vivo [25]. Therefore, progressive DA
neuronal death induced by striatal injection of 6-OHDA does not
appear to require caspase-3 activation.
Our current observations suggest that DA neuronal death is
mediated by the AIF pathway, because degenerating DA neurons
in WT mice exhibited nuclear translocation of AIF. AIF is a
mitochondrial flavoprotein that mediates caspase-independent cell
death [48,49,50,51]. In healthy cells, mitochondrial AIF may
protect against oxidative stress, but once released into the cytosol,
AIF is translocated to the nucleus where it directly induces
chromatin condensation and chromatolysis in a caspase-indepen-
dent manner. The release of AIF is modulated by mitochondrial
outer membrane permeabilization (MOMP), which is partly
regulated by the Bcl-2 family proteins, including Bax [52,53].
Bax can alter mitochondrial membrane permeability by forming
pores after oligomerization, or modulating existing channels like
VDAC [54,55], and modulation of Bcl-2/Bax dictates cellular fate
by increasing mitochondrial outer membrane permeability and
AIF release [52,56]. In this study, we found that AIF translocation
was completely absent in Bax-KO mice, indicating that AIF
translocation following 6-OHDA-induced DA neuronal death is
Bax-dependent. Increasing evidence supports a prominent role of
AIF in neurodegeneration, including PD. AIF translocation occurs
after toxic insults, including traumatic brain injury [57], oxidative
stress [58], cerebral ischemia [59], Alzheimer’s disease [60], and
MPTP-induced PD models [13]. Recently, nuclear translocation
of AIF was also found in the degenerating DA neurons in autopsies
of human PD patients, suggesting that AIF activation plays a
significant role in the DA neuronal death in PD patients [56].
It appears that AIF is preferentially released from the
mitochondria via a Bax-induced mitochondrial pore, because
AIF-translocated WT neurons maintained mitochondrial cyto-
Figure 4. Striatal innervation of TH-immunoreactive DA fibers 6 weeks after 6-OHDA treatment. Distribution of DA fibers were examined
at the nigrostriatal bundle (NSB, A–D), posterior striatum (Post Str, E–H), and anterior striatum (Ant Str, I–L) of CON (A, C, E, G, I, K) and IPSI (B, D, F,
H, J, L) sides of WT (A, B, E, F, I, J) and Bax-KO (C, D, G, H, K, L) mice. Insets in the I–L demonstrate the higher magnification images. Scale
bar=100 mm. M, N: Quantification of TH intensities on 2 weeks and 6 weeks after 6-OHDA treatment at the posterior striatum (M) and anterior
striatum (N) of WT and Bax-KO mice. Data are expressed as mean6s.e.m. n=3, *P,0.05 in Student’s t test comparison with control (CON) vs.
ipsilateral (IPSI) sides, and **P,0.05 in Student’s t-test comparison with WT vs. Bax-KO mice.
doi:10.1371/journal.pone.0025346.g004
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before the cytochrome C release during NMDA (N-methyl-D-
aspartate)-induced neuronal death [61,62,63]. It is known that AIF
is localized in the intermitochondrial space, and can be released by
calpain-dependent protein cleavage [64,65]. Some AIF proteins
are also localized in the outer mitochondrial membrane on the
cytosolic side [66], and may be released without calpain activation
[67]. On the other hand, cytochrome C is anchored to the
mitochondrial membrane by conjugation with the mitochondrial
membrane lipid cardiolipin [68,69]. Therefore, cytochrome C
release is dependent on the peroxidation of cardiolipin [70], and
distinct anchorage and release mechanisms of AIF and cyto-
chrome C may explain the preferential release of AIF via a Bax-
induced mitochondrial pore. Furthermore, it is known that
expression of Apaf-1 is down-regulated in mature neurons, making
neurons difficult to form apoptosome under the low concentration
of cytosolic cytochrome C [71]. Therefore, similar mechanisms
may also contribute to the selective activation of AIF pathway in
progressively degenerating DA neurons.
Although Bax-KO mice exhibited a complete absence of DA
neuronal death and partial restoration of DA fibers in the striatum
6 weeks after 6-OHDA treatment, there was no significant
improvement in PD-related neurological deficits in Bax-KO mice.
It is known that intrastriatal supplement of neurotrophic factors,
such as glial cell-derived neurotrophic factor (GDNF), is more
potent than the nigral supplement for the regeneration of striatal
DA fibers and functional recovery, although nigral GDNF delivery
was more potent for the survival of DA neurons from 6-OHDA-
induced neurodegeneration [72,73]. Because Bax deletion pri-
marily affects the survival of DA neuronal cell body, insufficient
regeneration/recovery at the striatal level may cause the failure in
the functional improvements. Supporting this, we found that DA
contents in Bax-KO ipsilateral striatum was markedly reduced,
although it was higher than WT littermates. Furthermore, we
currently do not know whether DA fibers in the Bax-KO
ipsilateral striatum are functional and efficiently releasing DA,
and thus we cannot completely rule out the possibility that not
only the number, but also the quality of DA fibers in Bax-KO mice
are insufficient for the functional recovery.
In conclusion, our present study provides evidence that striatal
injection of 6-OHDA induces Bax-dependent, AIF-mediated DA
neuronal death. However, neuronal atrophy appears to be a Bax-
independent mechanism, and Bax-KO mice did not exhibit
behavioral benefits. These results demonstrate the potentials and
limitations of a therapeutic strategy for anti-Bax treatment of PD.
Materials and Methods
Animals and surgery
Bax-KO mice were obtained from Jackson Laboratory (Bar
Harbor, ME), and maintained as heterozygotes on a C57BL/6
background. Homozygous mice were obtained by breeding
heterozygote male and female mice, and the genotypes of the
sibling animals were individually assessed by polymerase chain
reaction (PCR) as previously described [74]. For stereotaxic
injection of neurotoxin, adult male mice (25–30 g) were deeply
anesthetized with sodium pentobarbital (50 mg/kg) and placed in
a stereotaxic device (Stoelting, Wood Dale, IL). Neurotoxin, 6-
OHDA (15 mg in 1.5 ml of PBS containing 0.02% ascorbate), was
injected into the right striatum (anterior, +0.05 mm; medial,
20.2 mm; dorsal, 20.35 mm relative to bregma) by a 30-gauge
microsyringe at a rate of 0.5 ml/min. After a pause for 15 min, the
needle was slowly withdrawn.
For retrograde tracing, some animals received bilateral injection
of 1 ml retrograde fluorescent tracer Alexa Fluor 488-conjugated
Cholera Toxin Subunit B (CTx-B; Molecular probes, Eugene,
OR) into the striatum (anterior, +0.06 mm; medial, 20.22 mm;
dorsal, 20.35 mm relative to bregma) 7 days before a 6-OHDA
injection. All experiments were carried out in strict accordance
with the ethical guidelines of Korea University, and with the
approval of the Animal Care and Use Committee of Korea
University (Permit Number: KUIACUC-2011-127).
Histology
For immunohistochemical analysis, mice were perfused with 4%
paraformaldehyde and the brains were isolated. Following post-
fixation in the same fixative overnight, brains were cryoprotected
in 30% sucrose, sectioned serially (40 mm), and stored in 50%
glycerol/50% PBS solution at220uC until use. Every 6
th or 12
th
section containing the SN was blocked with 3% BSA in PBS for
30 min. Primary antibodies were then applied to the sections
overnight at room temperature. Primary antibodies used in this
study were a rabbit polyclonal tyrosine hydroxylase (TH; 1:1000;
Millipore, Temecula, CA), a mouse monoclonal TH (1:500;
Sigma, St. Louis, MO), rabbit polyclonal phosphorylated-c-Jun
(1:250; Cell Signaling, Beverly, MA), sheep cytochrome c (1:500;
Sigma), rabbit monoclonal AIF (1:250; Epitomics, Burlingame,
Figure 5. Absence of PD-related behavioral improvement in
Bax-KO mice. A: Cylinder test. At 2 and 6 weeks after 6-OHDA
injection, the rate of ipsilateral forelimb use was measured in WT (n=6)
and Bax-KO (n=4) mice. B: Apomorphine rotation test. The total scores
of ipsilateral rotation in 1 hr were scored in WT and Bax-KO mice. Tests
were done 6 weeks after 6-OHDA treatment. Data are expressed as
mean6s.e.m, n=6 (WT), n=4 (Bax-KO).
doi:10.1371/journal.pone.0025346.g005
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washes with PBS, sections were incubated with appropriate
secondary antibodies for 30 min. Nuclei were then counterstained
with Hoechst33342, and the images were captured with a Zeiss
LSM510 confocal microscope. For the measurement of the
intensity of TH-immunoreactivity, all images were captured under
the identical condition, and the intensity within the cell body or in
the striatum was obtained using the ImageJ program (http://
rsbweb.nih.gov/ij/).
Stereological analysis
To quantify the number of TH-positive (TH+) neurons, an
optical dissector method of stereological analysis was employed
[74]. Using StereoInvestigator Software (MicroBrightField, Will-
ston, VT), a fractionator probe was established for each section,
and every 6
th section covering the entire SN was examined. The
number of TH-positive neurons in each counting frame was then
determined by focusing down through the section, using a 406
objective. Our criteria for counting an individual TH+ neuron was
the presence of its nucleus within the counting frame, or touching
the right or top lines (green), but not touching the left or bottom
lines (red). The total number of TH+ neurons in each section of
the SN was then mathematically calculated by the Stereo
Investigator program.
Western blotting
For acquirement of SN, brain was rapidly frozen on dry ice, and
placed on a cryostat. Coronal slices (0.5 mm) containing SN were
taken, and SN region was punched out with 1.0 mm micro-punch.
Punched tissues were homogenized in ice-cold homogenization
buffer (250 mM sucrose, 10 mM HEPES, 1 mg/ml BSA, 0,5 mM
EDTA and 0.5 mM EGTA, pH 7.4) using a hand-held Tefalon
glass homogenizer (0.1 ml) by three gentle strokes and centrifuged
at 20006g for 3 min. Supernatant was centrifuged at 12,0006g
for 8 min, and the supernatant was taken as a cytosolic faction.
The pellet was then washed with sucrose buffer (320 mM sucrose,
3 mM CaCl2, 2 mM Mg?acetate, 0.1 mM EDTA, 10 mM Tris-
HCl, pH 8.0) and re-centrifuged at 12,0006g for 10 min. The
final pellet was resuspended in sucrose buffer (mitochondrial
fraction). Same amount (10 mg) of mitochondrial fraction and
cytosolic fraction was size-seperated through denaturing SDS-
PAGE. Primary antibodies used were a rabbit polyclonal TH
(1:1000; Abcam, Cambridge, MA), a mouse monoclonal cyto-
chrome C (1:1000; Pharmingen, San Diego, CA), and a goat
VDAC (1:1000; SantaCruz Biotechnonogy, Santa Cruz, CA). The
blot was washed, hybridized with appropriate secondary antibod-
ies, and the signal was detected using a Supersignal ChemiLumi-
niscence detection kit (Pierce, Rockford, IL) as described by
manufacturer.
HPLC
The levels of DA in the brain tissues were determined by a
modified method [75]. The tissue was homogenized with a tip in
280 ml of 0.2 M perchloric acid containing 0.1 mM EDTA and
20 mlo f1 0mM 3,4-Dihydroxybenzylamine hydrobromide as an
internal standard. Cell membranes were disrupted using a handy
sonicator (Tomy Seiko, Tokyo, Japan) in an ice bath and spun
down at 13,000 rpm for 10 min at 4uC using a centrifuge. The
supernatants were filtered through centrifugal filter devices
(Microcon YM-10, Millipore Co., Bedford, MA, USA) by
centrifuging at 13,000 rpm for 15 min at 4uC. After filtration,
20 ml of the sample was injected directly into an injector (7725i,
Rheodyne, Cotati, CA, USA) and analyzed by a high-performance
liquid chromatograph (HPLC) with electrochemical detection.
The pellets were used for measurements of protein concentration.
The HPLC system consisted of an electrochemical detector (ECD-
300, EICOM, Kyoto, Japan), a solvent delivery system (515
HPLC-pump; Waters Co., Milford, MA, USA), a column oven
(Waters Co., Milford, MA, USA), and a data processor
dsCHROM-net (Donam Int., Seoul, Korea). The separation
column was a reverse-phase C18 column (3.0 mm i.d.6150 mm;
EICOMPAK SC-50DS; EICOM) and the guard column was a
PREPAK (4.0 mm i.d.65 mm, EICOM). The appendance
potential of ECD-300 (carbon electrode vs. Ag/AgCl reference
electrode) was set at +750 mV. The mobile phase consisted of
90 mM sodium acetate–100 mM citric acid buffer (pH 3.5)/
methanol (83:17, v/v) containing 190 mg/L of sodium-1-octane-
sulfonic acid and 5 mg/L of 2Na EDTA. The flow rate was set at
0.5 ml/min at 30uC. 3,4-Dihydroxybenzylamine hydrobromide
was used as the internal standard for the quantification of DA
concentrations. DA levels were calculated using DA standard (3-
hydroxydopamine; dopaminehydrochloride) and corrected by
protein levels of the samples. The levels of DA were expressed
as ng/mg protein.
Behavioral tests
Preference of forelimb use during explorative activity was
analyzed in the cylinder test [33]. The test was performed from 1
to 6 weeks after 6-OHDA injection. Mice were placed individually
in a glass cylinder (11-cm diameter, 30-cm height) for 10 min, and
an experimenter who was blinded to the group counted the
number of wall contacts and landing contacts made with the
forepaws. The preference of the forelimb use was then scored by
the following equation: [L/(L+R)]6100, where L is the number of
left forelimb use, and R is the number of right forelimb use during
the test periods.
For rotation tests, mice were given 0.5 mg/kg apomorphine6-
weeks after 6-OHDA injection. Immediately after injection of
apomorphine, the animals were individually placed in a test bowl,
and the number of rotations made clockwise was monitored for
60 min [32].
Statistical analysis
Statistical significance of differences between the groups was
evaluated by two-tailed (a=0.05) one-way ANOVA with Scheffe’s
multiple comparison or independent sample t-tests. All the
analyses were carried out with SPSS software, and all values are
given as mean 6 SEM.
Supporting Information
Figure S1 Comparison of the soma size of TH immunoreactive
DA neurons between 2-weeks WT (open bars) vs. 2- (grey bars) or
6-weeks (black bars) Bax-KO groups in CON (left upper graph)
and IPSI (right upper) sides. Comparison of soma sizes between
CON and IPSI sides in 2-weeks WT (left lower graph) vs. 2- and 6-
weeks Bax-KO (right lower graph) groups. Most Bax-KO DA
neurons which were survived 2 weeks after 6-OHDA treatment
exhibited the reduction of the soma size, similar to the WT mice.
On the other hand, TH+ neurons in 6 weeks-old Bax-KO mice
exhibited partial recovery of soma size. Furthermore, small
fraction of Bax-KO DA neurons exhibited hypertrophy. For
example, the proportion of DA neurons with soma size .480 mm
2
was significantly increased in 6-weeks Bax-KO IPSI group. This
neuronal hypertrophy is known to be associated with regenerative
processes after neuronal injury [76], indicating the partial
regeneration in Bax-KO mice.
(TIF)
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